Carlos Hernando Barcenas

12PUBLICATIONS
44CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Midwifery not elsewhere classifiedMolecular targetsLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 28, 2026
Chemotherapy Declination Among Patients With Early-Stage Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer and High Oncotype DX Recurrence Scores.

|Feb 12, 2026
Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors.

Jasmine S Sukumar, Akshara S Raghavendra, Sarah Pasyar

|Jan 28, 2026
Prevalence and Outcomes of HER2-Low Versus HER2-0 Status in Patients with Metastatic Breast Cancer.

Akshara Singareeka Raghavendra, Diane D Liu, Senthil Damodaran

|Jan 12, 2026
Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer.

Akshara Singareeka Raghavendra, Senthil Damodaran, Carlos H Barcenas

|May 28, 2025
Anti-Obesity Medications and the Risk of Obesity-Related Cancers in Older Women: A Propensity Score Matching Analysis of 2007-2015 SEER-Medicare Data.

|May 19, 2025
Liquid biopsy in advanced and metastatic breast cancer: translating prognostic value to clinical implementation.

Chelain R Goodman, Carlos H Barcenas

Pageof 2

Frequent Collaborators

6 joint publications

Debu Tripathy

6 joint publications

Akshara Singareeka Raghavendra

3 joint publications

Yisheng Li

2 joint publications

Michael Roth